Pulmonary Outcomes Associated with Long-Term Azithromycin Therapy in Cystic Fibrosis

Rationale: Chronic azithromycin is commonly used in cystic fibrosis based on short controlled clinical trials showing reductions in pulmonary exacerbations and improved FEV(1). Long-term effects are unknown. Objectives: Examine pulmonary outcomes among chronic azithromycin users compared with matche...

Descripción completa

Detalles Bibliográficos
Autores principales: Nichols, Dave P., Odem-Davis, Katherine, Cogen, Jonathan D., Goss, Christopher H., Ren, Clement L., Skalland, Michelle, Somayaji, Ranjani, Heltshe, Sonya L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Thoracic Society 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049934/
https://www.ncbi.nlm.nih.gov/pubmed/31661302
http://dx.doi.org/10.1164/rccm.201906-1206OC

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049934/
https://www.ncbi.nlm.nih.gov/pubmed/31661302
http://dx.doi.org/10.1164/rccm.201906-1206OC

Ejemplares similares